Page 11234..1020..»

Category : Testosterone Physicians

Pomerantz Law Firm Announces the Filing of a Class Action against Lipocine Inc. and Certain Officers LPCN – GlobeNewswire

NEW YORK, Nov. 15, 2019 (GLOBE NEWSWIRE) -- Pomerantz LLP announce that a class action lawsuit has been filed against Lipocine Inc. (Lipocine or the Company) (NASDAQ:LPCN) and certain of its officers. The class action, filed in United States District Court, for the District of Utah, and docketed under 19-cv-00906, is on behalf of a class consisting of investors who purchased or otherwise acquired Lipocine securities between March 27, 2019, and November 8, 2019, both dates inclusive (the Class Period), seeking to recover damages caused by Defendants violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the Exchange Act) and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.

If you are a shareholder who purchased Lipocine common shares within the Class Period, you have until January 14, 2020, to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at http://www.pomerantzlaw.com. To discuss this action, contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext. 9980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and number of shares purchased.

[Click here for information about joining the class action]

Lipocine is a specialty pharmaceutical company that focuses on the development of pharmaceutical products in the area of mens and womens health. The Companys primary development programs are based on oral delivery solutions for poorly bioavailable drugs. The Company has a portfolio of product candidates purportedly designed to produce pharmacokinetic characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability.

Lipocines lead product candidate is TLANDO (LPCN 1021), an oral testosterone replacement therapy. The Company has previously submitted New Drug Applications (NDA) for TLANDO twice and, both times, received Complete Response Letters (CRL) from the U.S. Food and Drug Administration (FDA) rejecting the NDAs. The Company received the first CRL in June 2016 and the second in May 2018.

On March 27, 2019, during pre-market hours, Lipocine issued a press release announcing new topline results from a study evaluating TLANDOs effects on blood pressure (one issue cited by the FDA in a prior CRL rejecting TLANDOs NDA), as well as the Companys intention to refile the NDA for TLANDO in the second quarter of 2019 (the March 2019 Press Release).

The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Companys business, operational and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) the results from Lipocines clinical studies of TLANDO were insufficient to demonstrate the drugs efficacy; (ii) accordingly, Lipocines third NDA for TLANDO was highly likely to be found deficient by the FDA; and (iii) as a result, the Companys public statements were materially false and misleading at all relevant times.

On November 11, 2019, Lipocine issued a press release announcing receipt of a CRL from the FDA regarding its NDA for TLANDO. In the press release, Lipocine advised investors that the FDA had again rejected the NDA for TLANDOthis time because an efficacy trial had not met three of its secondary endpoints.

On this news, Lipocines stock price fell $1.93 per share, or 70.7%, to close at $0.80 per share on November 11, 2019.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See http://www.pomerantzlaw.com.

CONTACT:Robert S. WilloughbyPomerantz LLPrswilloughby@pomlaw.com

View post:
Pomerantz Law Firm Announces the Filing of a Class Action against Lipocine Inc. and Certain Officers LPCN - GlobeNewswire

Recommendation and review posted by Alexandra Lee Anderson

Testosterone Replacement Therapy Industry: Time to Invest in emerging Markets | Endo International, Pfizer, Novartis – News Description

AMA recently published a detailed study of over 180+ pages in its repository on Testosterone Replacement Therapy market covering interesting aspects of market with supporting development scenario till 2025. The study provides market size break-up by revenue and volume* for emerging countries and important business segments along with commentary on trending factors, growth drivers. Profiled players in study from the coverage used under bottom-up approach are AbbVie Inc. (United States), Endo International (Ireland), Eli Lilly and Company (United States), Pfizer (United States), Bayer (Germany), Actavis (Allergan) (United States), Novartis (Switzerland), Teva (Israel), Ferring Pharmaceuticals (Switzerland), Kyowa Kirin (Japan), Mylan (United States)

Next step one should take to boost sales? Track latest strategic steps and current scenario analysis of the market @ https://www.advancemarketanalytics.com/sample-report/46424-global-testosterone-replacement-therapy-market

Testosterone is responsible for the development of male sexual characteristics and this hormone formed by the testicles. Insufficient production of testosterone causes erectile dysfunction. Testosterone Replacement Therapy (TRT) is generally termed as hormone therapy for men, designed to counteract the effects of reduced activity in the gonads or hypogonadism. Hypogonadism in men is clinical syndrome, which results in the failure of the testes to produce physiological levels of testosterone. Erectile dysfunction arises due to reduce testosterone production to overcome this testosterone replacement therapy is used to improve the problem.

Market Segmentationby Type (Creams or Gels, Patches, Injections, Buccal Adhesives, Implants, Oral), Application (Hospitals, Clinics)

Make an enquiry before buying this Report @ https://www.advancemarketanalytics.com/enquiry-before-buy/46424-global-testosterone-replacement-therapy-market

Whats Trending in Market: Increasing awareness about testosterone substitute therapy

Growth Drivers: Increasing prevalence of hypogonadism in adult men

The need for having an offspring amongst men

Restraints: High possibility of side effects related to testosterone replacement therapy

View Detailed Table of Content @ https://www.advancemarketanalytics.com/reports/46424-global-testosterone-replacement-therapy-market

Country level Break-up includes:North America (United States, Canada and Mexico)Europe (Germany, France, United Kingdom, Spain, Italy, Netherlands, Switzerland, Nordic, Others)Asia-Pacific (Japan, China, Australia, India, Taiwan, South Korea, Middle East & Africa, Others)

Try a limited scope research document specific to Country or Regional matching your objective.

GET FULL COPY OF United States Testosterone Replacement Therapy market study @ USD 2000

And, Europe Testosterone Replacement Therapy market study @ USD 2500 Major Highlights of TOC:

Chapter One: Market Overview

Scope/Objective of the Study

Chapter Two: Executive Summary - Free of Cost

Chapter Three: Market Dynamics USD400

Market Drivers, Market Challenges, Market Trends

Chapter Four: Market Factor Analysis USD400

Supply/Value Chain Analysis, Porters Five Forces, PESTEL analysis, Market Entropy, Patent & Trademark Analysis, Market Development Scenario

Chapter Five and Seven: Global Testosterone Replacement Therapy, by Market Segmentation and Region (value, volume**) (2013-2024) USD2400

Global Testosterone Replacement Therapy

By Type (Creams or Gels, Patches, Injections, Buccal Adhesives, Implants, Oral)

By Application (Hospitals, Clinics)

Global Testosterone Replacement Therapy Region

North America (United States, Canada and Mexico)

Europe (Germany, France, United Kingdom, Spain, Italy, Netherlands, Switzerland, Nordic, Others)

Asia-Pacific (Japan, China, Australia, India, Taiwan, South Korea, Middle East & Africa, Others)

Chapter Six: Global Testosterone Replacement Therapy Manufacturers/Players Analysis USD1200

Competitive Landscape (Direct & Indirect Competitors), Market Share Analysis, Peer Group Analysis (2018), BCG Matrix, Company Profile, Downstream Buyers & Upstream Suppliers

..

Chapter Nine: Methodology/Research Approach, Data Source, Disclaimer

** If applicable

* Customized Section/Chapter wise Reports or Regional or Country wise Chapters are also available.

Buy this report @ https://www.advancemarketanalytics.com/buy-now?format=1&report=46424

Thanks for reading this article, you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

Contact Us: CRAIG FRANCIS (PR & Marketing Manager)[emailprotected]Ph: +1 (206) 317 1218

More here:
Testosterone Replacement Therapy Industry: Time to Invest in emerging Markets | Endo International, Pfizer, Novartis - News Description

Recommendation and review posted by Alexandra Lee Anderson

Testosterone Replacement Therapy: Controversy and Trends – Medscape

Abstract and Introduction Abstract

In recent years, testosterone replacement therapy (TRT) has received significant media attention, and the rate of testosterone use has increased notably. A reported association between testosterone use and increased occurrence of myocardial infarction and stroke prompted the FDA to issue a safety bulletin in 2014. Clinical hypogonadism is the only FDA-approved indication for TRT in men; it is not approved to treat age-related low testosterone. Although it is not indicated, TRT is often recommended to improve sexual function, bone density, body composition, muscle strength, mood, behavior, and cognition. The literature on the effectiveness of TRT for various conditions is largely mixed; therefore, current data on appropriate and potentially inappropriate use are important for pharmacists to keep abreast of and discuss with patients.

Recently, the use of testosterone replacement therapy (TRT) has received a lot of media attention. Although its use is growing, there is much debate regarding TRT's risks and benefits.[1] From 2008 to 2012 in the United States, spending on TRT increased from $1 billion to $2 billion, and from 2003 to 2013 there was a fourfold increase in the rate of TRT in men aged 18 to 45 years.[2] In 2013 and early 2014, two studies reported an association between TRT and increased occurrence of myocardial infarction and stroke, prompting the FDA to issue a safety bulletin on January 31, 2014.[3] This article will discuss appropriate TRT use, available formulations and cost, side effects, trends, and the pharmacist's role in patient education, including counseling points.

Link:
Testosterone Replacement Therapy: Controversy and Trends - Medscape

Recommendation and review posted by Alexandra Lee Anderson

LPCN LOSSES ALERT: Bernstein Liebhard LLP Reminds Investors of Its Investigation of Lipocine Inc – Yahoo Finance

NEW YORK, NY / ACCESSWIRE / November 11, 2019 / Bernstein Liebhard, a nationally acclaimed investor rights law firm, is investigating potential securities fraud claims on behalf of shareholders of Lipocine Inc. ("Lipocine" or the "Company") (LPCN) resulting from allegations that Lipocine might have issued misleading information to the investing public.

If you purchased Lipocine securities, and/or would like to discuss your legal rights and options please visit LPCN Shareholder Investigation or contact Matthew E. Guarnero toll free at (877) 779-1414 or MGuarnero@bernlieb.com.

On November 11, 2019, Lipocine announced that it had received a Complete Response Letter ("CRL") from the U.S. Food and Drug Administration regarding its New Drug Application for TLANDO, Lipocine's product candidate for testosterone replacement therapy. Lipocine advised investors, among other things, that "[t]he CRL identified one deficiency stating the efficacy trial did not meet the three secondary endpoints for maximal testosterone concentrations." On this news, Lipocine's stock price fell sharply during trading on November 11, 2019.

If you purchased Lipocine securities, and/or would like to discuss your legal rights and options please visit https://www.bernlieb.com/cases/lipocineinc-lpcn-shareholder-class-action-lawsuit-stock-fraud-218/apply/ or contact Matthew E. Guarnero toll free at (877) 779-1414 or MGuarnero@bernlieb.com.

Since 1993, Bernstein Liebhard LLP has recovered over $3.5 billion for its clients. In addition to representing individual investors, the Firm has been retained by some of the largest public and private pension funds in the country to monitor their assets and pursue litigation on their behalf. As a result of its success litigating hundreds of lawsuits and class actions, the Firm has been named to The National Law Journal's "Plaintiffs' Hot List" thirteen times and listed in The Legal 500 for ten consecutive years.

ATTORNEY ADVERTISING. 2019 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. The lawyer responsible for this advertisement in the State of Connecticut is Michael S. Bigin. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:Matthew E. GuarneroBernstein Liebhard LLPhttp://www.bernlieb.com(877) 779-1414MGuarnero@bernlieb.com

SOURCE: Bernstein Liebhard LLP

View source version on accesswire.com: https://www.accesswire.com/566097/LPCN-LOSSES-ALERT-Bernstein-Liebhard-LLP-Reminds-Investors-of-Its-Investigation-of-Lipocine-Inc

Link:
LPCN LOSSES ALERT: Bernstein Liebhard LLP Reminds Investors of Its Investigation of Lipocine Inc - Yahoo Finance

Recommendation and review posted by Alexandra Lee Anderson

Testosterone Replacement Therapy Market by application, Outlook and forecast 2019-2027 – Crypto Journal

The Testosterone Replacement Therapy Market Report is a valuable source of information for corporate strategists. This study contains comprehensive data that enhances the understanding, scope and application of this report. The report contains all the necessary information about the latest innovations, such as: For example, Porters five-pot model analysis and advanced profiles of elite industry participants.

The major players in the Testosterone Replacement Therapy Market investigated in this report are: AbbVie, Inc., Bayer AG, Endo Pharmaceuticals, Inc., Eli Lilly and Company, Kyowa Kirin International plc, Pfizer, Inc., Acerus Pharmaceuticals Corporation, and Perrigo Company plc.

Request a sample copy of this report @ https://www.coherentmarketinsights.com/insight/request-sample/2024

In the developing Markets of the Asia-Pacific, the Middle East, China, India, Japan and Australia, increased development prospects are to be expected due to the enormous potential in the individual countries. The various industry trends and threat factors are carefully examined and described in detail in this Testosterone Replacement Therapy report.

The study will also highlight the industrys key players, their product, business portfolio, Market share, financial status, regional share, segment sales, SWOT analysis, key strategies including mergers and acquisitions, product developments, joint ventures and partnerships, as well as improvements to their latest news.

In addition, this study will help our customers solve the following problems:

Cyclical Dynamics We forecast the dynamics of the industry through analytical and unconventional Market research approaches. Our customers use the information we provide to navigate Market uncertainty and disruption

Identifying Cannibalization Keys A major replacement for a product or service is the most common threat. Our customers can use our research findings to identify an important cannibalization of a Market. This helps them to prioritize their strategies for developing / delivering new products

Recognizing Emerging Trends Our range of ecosystems helps clients identify current Market trends. We also track possible impacts and disruptions that a Market would experience through a particular emerging trend. Our proactive analysis helps clients benefit from early intervention

Associated Opportunities With this report, customers can make decisions based on data, which increases the likelihood that the strategies in the real world will perform better, if not the best

For more information, see Download PDF Copy Here @ https://www.coherentmarketinsights.com/insight/request-pdf/2024

This study addresses some of the issues listed below:

How big is the Testosterone Replacement Therapy Market worldwide?

Which screen size is most preferred by consumers of Testosterone Replacement Therapy?

What type of distribution channel is most preferred by the producers of Testosterone Replacement Therapy?

What is the preferred age group for forwarding Testosterone Replacement Therapy to manufacturers?

What are the key factors that inhibit the growth of the Market, and to what extent are these factors affecting drivers and restraint systems?

How are the regulations affecting the growth of the Testosterone Replacement Therapy Market?

Which is the leading region / country for the growth of the Market? What is the expected growth rate of the leading regions in the forecasting period?

How will the emerging Testosterone Replacement Therapy Market develop in the coming years? How should the consumption pattern develop in the future?

Who are the main players in the global Testosterone Replacement Therapy Market? What is the current Market position of the key players? Who are the emerging players in this industry?

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Name: Mr. Raj Shah

Phone: US +12067016702 / UK +4402081334027

Email: [emailprotected]

Visit our Blog: https://hospitalhealthcareblog.wordpress.com/

Read the original:
Testosterone Replacement Therapy Market by application, Outlook and forecast 2019-2027 - Crypto Journal

Recommendation and review posted by Alexandra Lee Anderson

LPCN Awaits FDA Word, NKTR On Track, All’s Well With Five Prime’s FPT155 – Nasdaq

(RTTNews) - Today's Daily Dose brings you news about Alnylam's new positive efficacy results from its ongoing phase II open-label extension (OLE) study of Lumasiran for the treatment of primary hyperoxaluria type; Five Prime's initial safety data from its phase I clinical trial of FPT155 in patients with advanced solid tumors; Lipocine's much-awaited catalyst; Mirati's initial efficacy data from a phase II trial of Sitravatinib in metastatic urothelial cancer patients and Nektar's 18-month follow-up data from its PIVOT-02 study.

Read on

Alnylam Pharmaceuticals Inc. (ALNY) announced new positive efficacy results from its ongoing phase II open-label extension (OLE) study of Lumasiran for the treatment of primary hyperoxaluria type 1.

Primary hyperoxaluria type 1 (PH1) is a rare disorder that mainly affects the kidneys. It results from the buildup of a substance called oxalate, which normally is filtered through the kidneys and excreted in the urine (Source: NIH).

The open-label extension phase II study of Lumasiran demonstrated a 76 percent mean maximal reduction in urinary oxalate excretion, with all patients achieving a urinary oxalate level at or below 1.5 times the upper limit of normal, and 68 percent of patients achieving a urinary oxalate level within the normal range (less than or equal to 0.46 mmol/24hr/1.73m2).

The Company has also initiated a new global phase III study of Lumasiran for the Treatment of advanced Primary Hyperoxaluria Type 1, dubbed ILLUMINATE-C. The primary study endpoint is set as the percent reduction in plasma oxalate from baseline to six months.

Alnylam expects to report initial results from the ILLUMINATE-C trial in late 2020.

ALNY closed Friday's trading at $93.03, up 1.63%.

Five Prime Therapeutics Inc. (FPRX) has said that initial safety data from its phase I clinical trial of FPT155 in patients with advanced solid tumors suggest that it may not cause the same safety issues seen with a prior molecule targeting CD28.

FPT155 is a novel therapeutic CD80-Fc fusion protein that directly engages CD28 to enhance its co-stimulatory T-cell activation activity without inducing super agonism.

In 2006, in a phase I trial of TGN1412, a compound that targets CD28, 6 healthy volunteers had experienced serious toxicity including multi-organ failure. The trial later came to be referred to as the "elephant man drug trial" because of the disastrous side effects like severe swelling of the head, the trial participants had suffered.

Five Prime noted that FPT155 was well tolerated at all dose levels, with no dose-limiting toxicities and no grade 4 or higher adverse events. Dose escalation with FPT155 is ongoing with the study currently enrolling patients at the 70 mg dose level.

FPRX closed Friday's trading at $3.89, unchanged from the previous day's close.

Lipocine Inc.'s (LPCN) testosterone replacement therapy TLANDO is still awaiting word from the FDA regarding approval. The regulatory agency's decision on TLANDO was on November 9, 2019.

TLANDO, formerly known as LPCN 1021, is a twice-a-day oral testosterone product candidate that is designed to help restore normal testosterone levels in hypogonadal men.

The FDA had turned down TLANDO in June 2016, citing deficiencies related to the dosing algorithm for the proposed label, and in May 2018, saying that the product could not be approved in its current form.

It remains to be seen if the third time will prove lucky for TLANDO.

LPCN closed Friday's trading at $2.73, down 2.50%.

Mirati Therapeutics Inc.'s (MRTX) initial efficacy data from a phase II trial of Sitravatinib in combination with OPDIVO in metastatic urothelial cancer patients with documented progression on a platinum-chemotherapy and checkpoint inhibitor, presented on Saturday, has shown that the compound has the potential to increase responsiveness in patients whose tumors are resistant to checkpoint inhibitors.

According to the Company, out of the 22 metastatic urothelial cancer patients who were evaluable for response with at least one radiographic scan, 1 patient achieved a confirmed Complete Response and 6 archived Partial Response. Twenty-one of the twenty-two evaluable patients achieved a Complete Response, Partial Response or stable disease.

The preliminary results from an ongoing phase I study of neoadjuvant Sitravatinib combined with OPDIVO in patients with resectable squamous cell carcinoma of the oral cavity, dubbed SNOW, showed that there was tumor reduction in all eight patients who were eligible for evaluation, including one complete pathological response. With a median follow-up of 31.4 weeks, all patients are alive with no disease recurrence to date, noted the Company.

MRTX closed Friday's trading at $104.78, up 6.92%.

Nektar Therapeutics (NKTR), on Saturday, presented 18-month follow-up data from a phase I/II study of Bempegaldesleukin in combination with Opdivo in previously untreated metastatic melanoma patients, dubbed PIVOT-02.

At a median time of follow-up of 18.6 months for 38 efficacy-evaluable patients, the confirmed objective response rate (ORR) was 53%, with 34% of patients achieving confirmed complete responses. Forty-two percent of patients achieved a maximum reduction of 100% in target lesions and DCR, also known as disease control rate (CR+ Partial Response + Stable Disease), was 74%.

The median percent reduction of target lesions from baseline was 61.5%. At a median time of follow-up of 18.6 months, the median duration of response has not been reached, with 85% of patients with responses having ongoing responses, noted the Company.

A phase III trial evaluating Bempegaldesleukin in combination with Opdivo versus Opdivo in first-line advanced melanoma patients is currently recruiting patients.

NKTR closed Friday's trading at $20.04, up 7.17%.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Original post:
LPCN Awaits FDA Word, NKTR On Track, All's Well With Five Prime's FPT155 - Nasdaq

Recommendation and review posted by Alexandra Lee Anderson

Incredible Growth of Testosterone Replacement Therapy Market Recent Study including Growth by 2026 – Health News Office

A Comprehensive research study conducted byKD Market Insightson Eye Testing Equipment Market- by Device {Slit Lamp, Biometer, Perimeter, Tonometer, Optical Coherence Tomography (OCT), Fundus Camera, Autorefractor and Keratometer, and Other Devices}, Application (General Examination, Glaucoma, Cataract, and Other Applications), and End User (Hospital, Eye Clinic, and Optometry Academic Institute) Global Opportunity Analysis and Industry Forecast, 2017-2025 report offers extensive and highly detailed historical, current and future market trends in the Global and regional/market. TheEye Testing Equipment Marketreport includes market size, growth drivers, barriers, opportunities, trends and other information which helps to find new opportunities in this market for the growth of the business through new technologies and developments.

The globaleye testing equipment marketwas valued at $2,638 million in 2017 and is expected to reach $3,914 million by 2025, registering aCAGR of 5.0%from 2018 to 2025. Ophthalmic diagnostic devices/eye testing equipment/optometry devices are used for detection and analysis of eye-related diseases such as refractive error, cataract, glaucoma, and diabetic retinopathy. These diagnostic devices are of utmost importance to provide proper treatment to the patients to avoid further damage to the vision or loss of vision.

Request for Sample @https://www.kdmarketinsights.com/sample/4184Considerable increase in the incidence of eye-associated disorders especially cataract and glaucoma across the globe has played a significant role in driving the growth of eye testing equipment market. Immediate treatment of people suffering from glaucoma is essential as glaucoma in severe cases may result in loss of vision permanently. This immediate attention is possible only when the patients undergo comprehensive eye examinations wherein eye testing devices are utilized for effective diagnosis. In addition, glaucoma is anticipated to be the leading cause of blindness among people in the age group of 60 years and above. Whereas, cataract is a condition wherein clouding of the lens occurs resulting in decreased vision, and its incidence has been on the rise over the years.

The globaleye testing equipment marketis segmented based on device, application, end user, and region. Based on device, the market is classified into slit lamp, biometer, perimeter, tonometer, optical coherence tomography (oct) scanner, fundus camera, autorefractor & keratometer, and other devices. The other devices include lensmeter, chart projector/visual acuity accessory/computerized visual acuity system, ophthalmoscope, and others. By application, it is categorized into general examination, glaucoma, cataract, and other applications. The end users covered in the study include hospital, eye clinic, and optometry academic institute. Based on region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

KEY BENEFITS FOR STAKEHOLDERSThe study provides an in-depth analysis of the global eye testing equipment market with the current trends and future estimations to elucidate the imminent investment pockets.A comprehensive analysis of the factors that drive and restrict the market growth is provided.A comprehensive quantitative analysis of the industry is provided from 2017 to 2025 to assist stakeholders to capitalize on the prevailing market opportunities.An extensive analysis of the key segments of the industry helps understand the trends in eye testing equipment globally.Key players and their strategies are provided to understand the competitive outlook of the industry.

KEY MARKET SEGMENTSBy Device Slit Lamp Biometer Perimeter Tonometer Optical Coherence Tomography (OCT) Fundus Camera Autorefractor and Keratometer Other Devices

By Application General Examination Glaucoma Cataract Other Applications

By End User Hospital Eye Clinic Optometry Academic Institute

By RegionNorth America U.S. Canada MexicoEurope Germany France UK Italy Spain Rest of EuropeAsia-Pacific Japan China India Australia South Korea Rest of Asia-PacificLAMEA Brazil Saudi Arabia South Africa Rest of LAMEA

KEY MARKET PLAYERS Carl Zeiss Metall Zug AG (Haag Streit) Topcon Corporation Nidek Co., Ltd. Escalon Novartis Canon Essilor Heine Optotechnik Luneau Technology

The other players in the value chain include (profiles not included in the report) Heidelberg Engineering GmBH Huvitz BON Optic Reichert Technologies Potec Visionix Tomey Corporation LuxVision

Browse Full Report with TOC @https://www.kdmarketinsights.com/product/eye-testing-equipment-market-amrTable of Contents:

CHAPTER 1: INTRODUCTION1.1. Report description1.2. Key benefits for stakeholders1.3. Key market segments1.4. Research methodology1.4.1. Secondary research1.4.2. Primary research1.4.3. Analyst tools & models

CHAPTER 2: EXECUTIVE SUMMARY2.1. CXO perspective

CHAPTER 3: MARKET OVERVIEW3.1. Market definition and scope3.2. Key findings3.2.1. Top investment pockets3.3. Porters five forces analysis3.4. Market share analysis, 20173.5. Market dynamics3.5.1. Drivers3.5.1.1. Rising prevalence of eye diseases across the globe3.5.1.2. Increase in the technological advancements in the field of ophthalmological diagnostics3.5.1.3. Increasing government initiatives to control visual impairment3.5.2. Restraints3.5.2.1. Dearth of skilled professionals3.5.2.2. Low accessibility to eye care in low income countries3.5.3. Opportunity3.5.3.1. Emerging nations offer profitable opportunities for eye testing equipment manufacturers

CHAPTER 4: EYE TESTING EQUIPMENT MARKET, BY DEVICE4.1. Overview4.1.1. Market size and forecast4.2. Slit Lamps4.2.1. Key trends and opportunities4.2.2. Market size and forecast4.2.3. Market analysis, by country4.3. Biometers4.3.1. Key trends and opportunities4.3.2. Market size and forecast4.3.3. Market analysis, by country4.4. Perimeters4.4.1. Key trends and opportunities4.4.2. Market size and forecast4.4.3. Market analysis, by country4.5. Tonometers4.5.1. Key trends and opportunities4.5.2. Market size and forecast4.5.3. Market analysis, by country4.6. Optical Coherence Tomography (OCT)4.6.1. Key trends and opportunities4.6.2. Market size and forecast4.6.3. Market analysis, by country4.7. Fundus Cameras4.7.1. Key trends and opportunities4.7.2. Market size and forecast4.7.3. Market analysis, by country4.8. Autorefractors and Keratometers4.8.1. Key trends and opportunities4.8.2. Market size and forecast4.8.3. Market analysis, by country4.9. Other Devices4.9.1. Key trends and opportunities4.9.2. Market size and forecast4.9.3. Market analysis, by country

CHAPTER 5: EYE TESTING EQUIPMENT MARKET, BY APPLICATIONS5.1. Overview5.1.1. Market size and forecast5.2. General Eye Examinations5.2.1. Market size and forecast5.2.2. Market analysis, by country5.3. Glaucoma5.3.1. Market size and forecast5.3.2. Market analysis, by country5.4. Cataract5.4.1. Market size and forecast5.4.2. Market analysis, by country5.5. Other Applications5.5.1. Market size and forecast5.5.2. Market analysis, by country

CHAPTER 6: EYE TESTING EQUIPMENT MARKET, BY END USER6.1. Overview6.1.1. Market size and forecast6.2. Hospitals6.2.1. Market size and forecast6.2.2. Market analysis, by country6.3. Eye Clinics6.3.1. Market size and forecast6.3.2. Market analysis, by country6.4. Optometry Academic Institutes6.4.1. Market size and forecast6.4.2. Market analysis, by country

CHAPTER 7: EYE TESTING EQUIPMENT MARKET, BY REGION7.1. Overview7.1.1. Market size and forecast7.2. North America7.2.1. Key trends and opportunities7.2.2. North America market size & forecast, by country7.2.2.1. U.S. market size & forecast, by device7.2.2.2. U.S. market size & forecast, by application7.2.2.3. U.S. market size & forecast, by end user7.2.2.4. Canada market size & forecast, by device7.2.2.5. Canada market size & forecast, by application7.2.2.6. Canada market size & forecast, by end user7.2.2.7. Mexico market size & forecast, by device7.2.2.8. Mexico market size & forecast, by application7.2.2.9. Mexico market size & forecast, by end user7.2.3. North America market size & forecast, by device7.2.4. North America market size & forecast, by application7.2.5. North America market size & forecast, by end user7.3. Europe7.3.1. Key trends and opportunities7.3.2. Europe market size & forecast for eye testing equipment market, by country7.3.2.1. Germany market size & forecast, by device7.3.2.2. Germany market size & forecast, by application7.3.2.3. Germany market size & forecast, by end user7.3.2.4. France market size & forecast, by device7.3.2.5. France market size & forecast, by application7.3.2.6. France market size & forecast, by end user7.3.2.7. UK market size & forecast, by device7.3.2.8. UK market size & forecast, by application7.3.2.9. UK market size & forecast, by end user7.3.2.10. Italy market size & forecast, by device7.3.2.11. Italy market size & forecast, by application7.3.2.12. Italy market size & forecast, by end user7.3.2.13. Spain market size & forecast, by device7.3.2.14. Spain market size & forecast, by application7.3.2.15. Spain market size & forecast, by end user7.3.2.16. Rest of Europe market size & forecast, by device7.3.2.17. Rest of Europe market size & forecast, by application7.3.2.18. Rest of Europe market size & forecast, by end user7.3.3. Europe market size & forecast, by device7.3.4. Europe market size & forecast, by application7.3.5. Europe market size & forecast, by end user7.4. Asia-Pacific7.4.1. Key trends and opportunities7.4.2. Asia-Pacific market size & forecast, by country7.4.2.1. Japan market size & forecast, by device7.4.2.2. Japan market size & forecast, by application7.4.2.3. Japan market size & forecast, by end user7.4.2.4. China market size & forecast, by device7.4.2.5. China market size & forecast, by application7.4.2.6. China market size & forecast, by end user7.4.2.7. India market size & forecast, by device7.4.2.8. India market size & forecast, by application7.4.2.9. India market size & forecast, by end user7.4.2.10. Australia market size & forecast, by device7.4.2.11. Australia market size & forecast, by applicationContinue.

Check for Discount @https://www.kdmarketinsights.com/discount/4184

About Us:

KD Market Insightsis one of the leading providers of market intelligence products and services. We offer reports on over 10+ industries and update our collection daily which helps our clients to access database of expert market insights on global industries, companies, products, and trends. Our in-house research experts have a wealth of knowledge in their respective domains. With KD Market Research, you always have the choice of getting customized report free of cost (up to 10%). Our support team will help you customize the report and scope as per your business needs. This ensures that you are making the right purchase decision.Our clients list includes various Fortune 500 companies and leading advisory firms.

Contact Us:KD Market Insights90 State Street, Albany,New York, USA 12207+1 (518) 300-1215Email:[emailprotected]Website:www.kdmarketinsights.comRead More News:https://foodcourt894109857.wordpress.com/https://automotiveindustry9.blogspot.com/

Read the original post:
Incredible Growth of Testosterone Replacement Therapy Market Recent Study including Growth by 2026 - Health News Office

Recommendation and review posted by Alexandra Lee Anderson

Insurer Can’t Blame Drug Cos. For Its Inaction, 7th Circ. Told – Law360

Law360, Chicago (November 6, 2019, 2:28 PM EST) -- A Seventh Circuit judge on Wednesday pushed Medical Mutual of Ohio to address why it waited until July 2016 to take steps to limit which testosterone replacement drugs the insurer would cover, two years after the U.S. Food and Drug Administration flagged potential cardiovascular risks associated with the drugs.

During oral arguments, Medical Mutual urged the Seventh Circuit to revive its Racketeer Influenced and Corrupt Organizations Act suit against AbbVie and other makers of testosterone replacement drugs, or TRTs, saying they misrepresented those drugs as being safe and effective for a host of symptoms related to normal male aging.

But U.S....

In the legal profession, information is the key to success. You have to know whats happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.

TRY LAW360 FREE FOR SEVEN DAYS

Read the original here:
Insurer Can't Blame Drug Cos. For Its Inaction, 7th Circ. Told - Law360

Recommendation and review posted by Alexandra Lee Anderson

Testosterone Replacement Therapy Market Published by Leading Research Firm – Maxi Wire

The globaltestosterone replacement therapy marketrides on the back of technology. As consumer focus shifts from access to comfort, players in the market for testosterone replacement therapy are looking at new opportunities to capitalize on the potential. This exclusive report from Transparency Market Research will take you through an extensive analysis of every aspect in the testosterone replacement therapy market that is critical for defining your success strategy. It offers prudent information on markets under currents, trends that will open new doors, factors that will remain important, challenges that need to be overcome, prevailing competition in the market, and the geographical landscape.

Based on a tested and proven research methodology, our research analysts bring to you fact-checked information. Besides presenting the current market figures, our analysts provide you with accurate forecasts that can be the game-changer for your winning strategies for tomorrow. On the other hand, our reports also offer tailor-made insights. Further, our reports are packed with experts viewpoints which are transcribed from interviews conducted by our analysts.

For Right Perspective & Competitive Insights,Request For A Sample Here

For every market, information on leading players can be the difference between success and failure, be it a prominent brand or not. Our reports cover every significant players in the global testosterone replacement therapy market providing information about the company profile, products, winning strategies and market revenues. Not just that, TMR also provides information on the competitive landscape, helping you understand what impacted in one company being the market leader and others not. It also explains on the companies imperatives that define their success in the global market for testosterone replacement therapy.

Healthcare, unlike most industries, is typical of the region. Humans have multiple races and hence their genetic makeups are different. As a result, one condition has different impacts depending on the region. Therefore, information on how consumer requirements are different in regional landscape of the global testosterone replacement therapy is provided her in the report. Further, the economic capabilities of a country has a huge impact on healthcare infrastructure. TMRs report analysis the current economic scenario and also brings to you information on affordability during the coming years.

To Clarify Your Doubts About The Report,Request A Brochure Here

From market share to region-specific strategies, the report covers it all. At the same time, players in the testosterone replacement therapy market who are looking to expand might want to assess the potential of a prospective region. Our reports can provide you with custom-made insights for specific regions in the global testosterone replacement therapy market. The geographical analysis also covers regions-specific factors that could turn out to be hurdle for growth in the coming years.

Original post:
Testosterone Replacement Therapy Market Published by Leading Research Firm - Maxi Wire

Recommendation and review posted by Alexandra Lee Anderson

Testosterone Replacement Therapy Market Top key Players, Size, Share, Demand, Opportunities And Forecasts To 2025 – Weekly Spy

Testosterone Replacement Therapy Market primary data collection was achieved by interviewing the retailers and the consumers. The interviews were conducted through one to one structured questionnaire supervision.

Global Testosterone Replacement Therapy Market report provides an in-depth analysis of all market dynamics including drivers and restraints, and trends and opportunities. Important factors supporting growth across various is also provided. Using the industrial figures, the market finds growth figures between the forecast timespan.

In order to present an executive-level model of the market and its future perspectives, Testosterone Replacement Therapy Market report presents a clear segmentation based on different parameters. The factors that affect these segments are also discussed in detail in the report.

Request Exclusive Free Sample PDF Of This Report At https://dataintelo.com/request-sample/?reportId=110389

Major Players included in this report are as follows

AbbVie Endo International Eli lilly Pfizer Actavis (Allergan) Bayer Novartis Teva Mylan Upsher-Smith Ferring Pharmaceuticals Kyowa Kirin Acerus Pharmaceuticals

Testosterone Replacement Therapy Market can be segmented into Product Types as

Gels Injections Patches Other

Testosterone Replacement Therapy Market can be segmented into Applications as

Hospitals Clinics Others

Testosterone Replacement Therapy Market: Regional analysis includes:Asia-Pacific (Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia)Europe (Turkey, Germany, Russia UK, Italy, France, etc.)North America (United States, Mexico, and Canada.)South America (Brazil etc.)The Middle East and Africa (GCC Countries and Egypt.)

The research provides answers to the following key questions: What is the global (North America, South America, Europe, Africa, Middle East, Asia, China, Japan) production, production value, consumption, consumption value, import and export of Testosterone Replacement Therapy? Who are the global key manufacturers of Testosterone Replacement Therapy industry? How are their operating situation (capacity, production, price, cost, gross and revenue)? What are the types and applications of Testosterone Replacement Therapy? What is the market share of each type and application? What are the upstream raw materials and manufacturing equipment of Testosterone Replacement Therapy? What is the manufacturing process of Testosterone Replacement Therapy? Economic impact on Testosterone Replacement Therapy industry and development trend of Testosterone Replacement Therapy industry. What will the Testosterone Replacement Therapy market size and the growth rate be in 2025? What are the key factors driving the global Testosterone Replacement Therapy industry? What are the key market trends impacting the growth of the Testosterone Replacement Therapy market? What is the Testosterone Replacement Therapy market challenges to market growth? What are the Testosterone Replacement Therapy market opportunities and threats faced by the vendors in the global Testosterone Replacement Therapy market?

For More Information on this report, Request Inquiry At https://dataintelo.com/enquiry-before-buying/?reportId=110389

Testosterone Replacement Therapy Market track and analyse competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, research and developments, with respect to the current market size and future prospective.

For Best Discount on purchasing this report, Visit https://dataintelo.com/ask-for-discount/?reportId=110389

About DataIntelo:DATAINTELO has set its benchmark in the market research industry by providing syndicated and customized research report to the clients. The database of the company is updated on a daily basis to prompt the clients with the latest trends and in-depth analysis of the industry.Our pool of database contains various industry verticals that include: IT & Telecom, Food Beverage, Automotive, Healthcare, Chemicals and Energy, Consumer foods, Food and beverages, and many more. Each and every report goes through the proper research methodology, validated from the professionals and analysts to ensure the eminent quality reports.

Read More Trending News at Top Special Reports

Contact Info Name Alex MathewsPhone +1 909 545 6473Email sales@dataintelo.comWebsite https://dataintelo.comAddress 500 East E Street, Ontario, CA 91764, United States.

Continue reading here:
Testosterone Replacement Therapy Market Top key Players, Size, Share, Demand, Opportunities And Forecasts To 2025 - Weekly Spy

Recommendation and review posted by Alexandra Lee Anderson


Page 11234..1020..»